LEVO-ALPHA ACETYL METHADOL (LAAM). ITS ADVANTAGES AND DRAWBACKS
Bewaard in:
FINN, P., WILCOCK, K., LEVO-ALPHA ACETYL METHADOL (LAAM). ITS ADVANTAGES AND DRAWBACKS. JOURNAL OF SUBSTANCE ABUSE TREATMENT, Vol. 14, no. 6 (1997), p. 559-564.
Ref.
64252
Plaats:
SIIS R.991
Palabras clave:
Alternativas, Drogodependencias, Innovaciones, Metadona, Opiáceos, Programas de bajo umbral, Programas de mantenimiento, Tratamiento
Alternativas, Drogodependencias, Innovaciones, Metadona, Opiáceos, Programas de bajo umbral, Programas de mantenimiento, Tratamiento
Gelijkaardige items: LEVO-ALPHA ACETYL METHADOL (LAAM). ITS ADVANTAGES AND DRAWBACKS
- NEVIRAPINE INDUCED OPIOID WITHDRAWAL IN A PATIENT PREVIOUSLY STABLE ON LEVO-ALPHA-ACETYL-METHADOL (LAAM)
- LEVO-ALPHA-ACETYLMETHADOL (LAAM) VERSUS METHADONE: TREATMENT RETENTION AND OPIATE USE
- THE USE OF LEVO-ALPHA-ACETYLMETHADOL (LAAM) IN METHADONE PATIENTS WHO HAVE NOT ACHIEVED HEROIN ABSTINENCE
- LEVO ALPHA ACETYLMETHADOL (LAAM) VERSUS METHADONE MAINTENANCE: 1 YEAR TREATMENT RETENTION, OUTCOMES AND STATUS
- AN ASSESSMENT OF THE POTENTIAL CROSS-REACTIVITY OF LEVO-ALPHA-ACETYLMETHADOL (LAAM) WITH URINE ASSAYS FOR METHADONE
- A RANDOMIZED TRIAL COMPARING LEVO-ALPHA ACETYLMETHADOL WITH METHADONE MAINTENANCE FOR PATIENTS IN PRIMARY CARE SETTING IN AUSTRALIA